Dataset Information


Gene expression profiling of L-540, SUP-HD1, KM-H2 and L-428 Hodgkin lymphoma cell lines after in vitro and in vivo treatment with the dual PI3K/ERK inhibitor AEZS-136

ABSTRACT: Disease relapse and resistance to chemotherapy represent challenging issues in a subset of Hodgkin Lymphoma (HL) patients. Activity and mechanism(s) of action of a novel PI3K/ERK dual inhibitor AEZS-136 (Æterna Zentaris GmbH, Germany, EU) were examined in L-540, SUP-HD1, KM-H2 and L-428 cell lines. Despite exposure to AEZS-136 induced a significant cell growth inhibition (range, 30-80%), levels of caspase-independent cell death and mitochondrial dysfunction, were only observed in L-540 (62 ±9 vs 14 ±3%, P ≤.0001) and SUP-HD1 (46 ±2% vs 15 ±2%, P ≤.0001) cells. Gene expression profiling indicated that the effects of AEZS-136 treatment are associated with the modulation of cell cycle and cell death pathways. Exposure to AEZS-136 resulted in sustained production of reactive oxygen species (ROS) and activation of necroptotic cell death. The necroptosis inhibitor Necrostatin-1 prevented AEZS-136-induced ROS production, mitochondrial injury, activation of JNK and cell death. Knockdown experiments identified the immediate early response 3 (IER3) as a key signaling molecule that mediates AEZS-136-resistance to oxidative death of HL cells. Furthermore, in vivo xenograft studies demonstrated a 40-70% reduction in tumor burden (P < 0.0001) and a 10-fold increase in tumor necrosis in AEZS-136-treated animals compared to control mice. These data support further clinical evaluation of AEZS-136 in refractory/relapsed HL. The Hodgkin lymphoma cell lines were obtained from the DSMZ (Braunschweig, Germany, EU). Cells were routinely maintained in RPMI medium 1640 (Lonza, Basel, Switzerland) supplemented with 20% FBS (Lonza) and 2 mM glutamine (Lonza). Cells were maintained at 37°C in a water-saturated atmosphere of 5% CO2 in air. 4x106 HL cells were seeded in 75 cm2 flask and, after 24 hrs, cells were treated with 10 µM AEZS-136 (Aeterna Zentaris, Frankfurt, Germany, EU) in culture medium for 24 hours. At the end of treatment, cells were collected and RNA extracted.

ORGANISM(S): Homo sapiens  

SUBMITTER: G G Stirparo   Giuliano Giuseppe Stirparo 

PROVIDER: E-GEOD-58899 | ArrayExpress | 2016-07-03



Similar Datasets

2016-07-03 | E-GEOD-71150 | ArrayExpress
| GSE31059 | GEO
| GSE65479 | GEO
2015-01-29 | E-GEOD-31058 | ArrayExpress
2015-01-29 | E-GEOD-31057 | ArrayExpress
2015-01-29 | E-GEOD-31059 | ArrayExpress
2015-03-01 | E-GEOD-65479 | ArrayExpress
2015-03-01 | E-GEOD-65483 | ArrayExpress
| GSE90992 | GEO
2009-04-11 | GSE15560 | GEO